My watch list
my.bionity.com  
Login  

9 Current news about the topic traumatic brain injuries

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
Advancing stem cell therapy with biodegradable scaffold

New technology is aimed at central nervous system diseases and injuries

06-Nov-2018

Rutgers scientists have created a tiny, biodegradable scaffold to transplant stem cells and deliver drugs, which may help treat Alzheimer's and Parkinson's diseases, aging brain degeneration, spinal cord injuries and traumatic brain injuries. Stem cell transplantation, which shows promise as a ...

more

Identifying trauma risk in small children early

25-Sep-2013

Small children also suffer from post-traumatic stress disorders after a serious accident. With the aid of a new test, children with an increased risk can already be identified in the space of a few days. The test devised by scientists from the University of Zurich and the University Children’s ...

more

Single concussion may cause lasting brain damage

14-Mar-2013

A single concussion may cause lasting structural damage to the brain, according to a new study. "This is the first study that shows brain areas undergo measureable volume loss after concussion," said Yvonne W. Lui, M.D., Neuroradiology section chief and assistant professor of radiology at NYU ...

more

Athersys Awarded $3.6 Million in Grant Funding For Stem Cell Product Development

Funding supports advancement for treatment of neurological and cardiovascular conditions & advanced manufacturing platform

03-Feb-2012

Athersys, Inc. announced grant funding aggregating $3.6 million to further advance its MultiStem® product programs and cell therapy platform. Specifically, Athersys was awarded a SBIR Fast-Track grant of up to $1.9 million from the National Institute of Neurological Disorders and Stroke (NINDS) ...

more

NeuroVive and to-BBB awarded Eurostars grant for development of stroke therapy

04-Oct-2011

NeuroVive Pharmaceutical AB and to-BBB have been awarded a grant of €1 million through the Eureka Eurostars program for the joint development of therapies for stroke and other acute neurological conditions.The Eurostars program has awarded NeuroVive Pharmaceutical and to-BBB technologies, a grant ...

more

NeuroVive and to-BBB to jointly develop therapy for stroke

27-Oct-2010

NeuroVive Pharmaceutical and to-BBB are entering into a joint program to develop therapies for stroke and other acute neurodegenerative diseases by combining their technologies. NeuroVive Pharmaceutical is engaged in research and development of nerve cell-protecting and regenerative ...

more

Allon completes dosing in Phase II cognitive impairment trial

27-May-2008

Allon Therapeutics Inc. announced it has completed the randomized portion of its Phase II human clinical trial evaluating the Company's product AL-208 as a treatment for the mild cognitive impairment (MCI) that commonly occurs following coronary artery bypass graft (CABG) surgery. The Company ...

more

KeyNeurotek Pharmaceuticals Reports Positive Phase I Data of Its Cannabinoid Receptor-Agonist

13-May-2008

KeyNeurotek Pharmaceuticals AG announced positive results of a Phase I study with its cannabinoid receptor-agonist KN38-7271. KN38-7271 is being developed for the treatment of patients suffering from acute neurodegenerative incidents like a stroke or traumatic brain injuries. All study endpoints ...

more

KeyNeurotek AG to Start European Phase II Trial in Traumatic Brain Injury (TBI)

18-Oct-2006

KeyNeurotek AG announced the start of a European Phase II trial of KN 38-7271 in traumatic brain injury (TBI) patients. The multi-center study of the cannabinoid receptor agonist will start in 12 clinics in Europe, including Germany and comprise more than 100 patients. The goal of the study is to ...

more

Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE